Caroline Heckman
机构: University of Helsinki, Institute for Molecular Medicine Finland FIMM-HiLIFE
主页: fimm.fi
每年引用次数
引用次数
引用: 7,340
H-指数: 39
I10-指数 : 78
出版物: 309
Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing
Matti Kankainen , Caroline A Heckman , Mika Kontro , Bhagwan Yadav
Blood 130 1398 -1398
2017
Elevated Expression of the S100A8/S100A9 Complex in AML Correlates with Reduced Sensitivity to the BCL2 Inhibitor Venetoclax
Caroline A Heckman , Riikka Karjalainen , Mika Kontro , Alun Parsons
Blood 130 298 -298
2017
Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients
Ville Varmavuo , Caroline A Heckman , Marjaana Säily , Esa Jantunen
Blood 136 20 -20
2020
Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA
David Tamborero , Samuli Eldfors , Caroline A Heckman , Esa Jantunen
Blood 130 4412 -4412
2017
Development of Novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia
Øystein Bruserud , Monica Hellesoy , Monica Hellesoy , Caroline A Heckman
Blood 130 3349 -3349
2017
Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles
Samuli Eldfors , Krister Wennerberg , Astrid Murumagi , Caroline A Heckman
Blood 130 854 -854
2017
Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen.
Alexander Schepsky , Caroline A Heckman , Juho J Miettinen , Peter O Gorman
Cancers 13 ( 7) 1527
22
2021
Identification of Progression-Associated Mutations in Chronic Myeloid Leukemia (CML) By Comparative Genomic Analysis
Satu Mustjoki , Samuli Eldfors , Pekka Ellonen , Matti Kankainen
Blood 130 250 -250
3
2017
Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types
Muntasir M Majumder , Maija Leppä , Monica Hellesoy , Paul Dowling
Blood 132 264 -264
2018
Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity
Mahesh Tambe , Ella Karjalainen , Markus Vaha-Koskela , Caroline A Heckman
Blood 132 2210 -2210
3
2018
Eltrombopag Promotes Megakaryocyte Survival and Signaling in the Presence of Specific Cytotoxic Agents
Komal Kumar Javarappa , Dimitrios Tsallos , Bulat Zagidullin , Joseph J Saad
Blood 132 3836 -3836
2018
Predictive Response Biomarkers for BET Inhibitors in AML
Joseph J Saad , Juho Miettinen , Dimitrios Tsallos , Samuli Eldfors
Blood 132 2749 -2749
2018
Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9
Riikka Karjalainen , Minxia Liu , Ashwini Kumar , Alun Parsons
Blood 132 2634 -2634
1
2018
Negative regulation of bcl-2 expression by p53 in hematopoietic cells
Yu-ling Wu , John W Mehew , Caroline A Heckman , Magdalena Arcinas
Oncogene 20 ( 2) 240 -251
202
2001
NF-κB activates Bcl-2 expression in t (14 ; 18) lymphoma cells
Caroline A Heckman , John W Mehew , Linda M Boxer
Oncogene 21 ( 24) 3898 -3908
159
2002
Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia
Ana Rio-Machin , Pedro Casado-Izquierdo , Juho Miettinen , Findlay Bewicke-Copley
Blood 136 39 -40
1
2020
DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors
Muntasir M Majumder , David Tamborero , Pekka Anttila , Raija Silvennoinen
Blood 128 ( 22) 198 -198
2016
Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia
Shady Adnan Awad , Matti Kankainen , Samuli Eldfors , Soili Kytölä
Blood 128 ( 22) 1924 -1924
2016
A High-Throughput Biology Approach to Identify Novel Therapies Specifically Targeting AML Blasts and Leukemic Stem Cells
Heikki Kuusanmäki , Aino Maija Leppä , Debashish Deb , Caroline A Heckman
Blood 128 ( 22) 2755 -2755
2016
Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma
Raija Silvennoinen , Muntasir Mamun Majumder , David Tamborero , Pekka Anttila
Blood 124 ( 21) 646 -646
2014